Literature DB >> 19028718

What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?

J M Blondeau1.   

Abstract

Clostridium difficile is recognized as a major cause of antibiotic-associated diarrhoea and colitis. Antimicrobial agents have been repeatedly recognized as a causative risk for C. difficile-associated diarrhoea (CDAD) and more recently fluoroquinolones have been particularly implicated. Unfortunately, not all reports of antimicrobial associations with CDAD have excluded variables other than antimicrobial use. Prevention of CDAD usually involves infection control interventions and antimicrobial restriction policies may not be fully substantiated by currently available data; however, antimicrobial drug restriction seems prudent in outbreak situations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028718     DOI: 10.1093/jac/dkn477

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

1.  An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Authors:  Scott M Baliban; Amanda Michael; Berje Shammassian; Shikata Mudakha; Amir S Khan; Simon Cocklin; Isaac Zentner; Brian P Latimer; Laurent Bouillaut; Meredith Hunter; Preston Marx; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

2.  Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.

Authors:  Jan J De Waele; Jose M Tellado; Günter Weiss; Jeffrey Alder; Frank Kruesmann; Pierre Arvis; Tajamul Hussain; Joseph S Solomkin
Journal:  Surg Infect (Larchmt)       Date:  2014-05-15       Impact factor: 2.150

Review 3. 

Authors:  Samiha Mohsen; James A Dickinson; Ranjani Somayaji
Journal:  Can Fam Physician       Date:  2020-09       Impact factor: 3.275

Review 4.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

5.  Surgical prophylaxis with gentamicin and acute kidney injury: a systematic review and meta-analysis.

Authors:  Weeraporn Srisung; Jirapat Teerakanok; Pakpoom Tantrachoti; Amputch Karukote; Kenneth Nugent
Journal:  Ann Transl Med       Date:  2017-03

6.  The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.

Authors:  Angela E Reeves; Casey M Theriot; Ingrid L Bergin; Gary B Huffnagle; Patrick D Schloss; Vincent B Young
Journal:  Gut Microbes       Date:  2011-05-01

7.  Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.

Authors:  Casey M Theriot; Charles C Koumpouras; Paul E Carlson; Ingrid I Bergin; David M Aronoff; Vincent B Young
Journal:  Gut Microbes       Date:  2011-11-01

8.  Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018.

Authors:  Patrizia Spigaglia; Fabrizio Barbanti; Anna Maria Dionisi; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

Review 9.  Update on the adverse effects of antimicrobial therapies in community practice.

Authors:  Samiha Mohsen; James A Dickinson; Ranjani Somayaji
Journal:  Can Fam Physician       Date:  2020-09       Impact factor: 3.275

Review 10.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.